Multicenter prospective intervention study to evaluate the efficacy of prophylaxis for venous thromboembolism with antithrombotic drugs in Japanese inflammatory bowel disease inpatients. - Efficacy of prophylaxis for venous thromboembolism with antithrombotic drugs in Japanese IBD inpatients.

Asahikawa Medical Universtity0 个研究点目标入组 170 人开始时间: 2017年12月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who have 2 or more decrease of hemoglobin concentration within 1 week, or active intestinal bleeding defined as Mayo bleeding score 3 (Intestinal bleeding in Crohn disease is assessed based on Mayo score). Patients with active phase who are assessed as unqualified for antithrombotic therapy by doctor in charge in spite of unmatched above criteria. 2) Patients who are bleeding or have possibility of bleeding, such as peptic ulcer in gastrointestinal tract and hematological disorder having the tendency of bleeding (disseminated intravascular coagulation, idiopathic thrombocytopenic purpura, hemophilia). 3) Patients who have severe hepatic and/or renal dysfunction. 4) Patients who have allergy against UFH. 5) Patients who have the past histories of heparin-induced thromobocytopenia. 6) Patients who take antithrombotic therapy other than UFH, such as antiplatelet drugs, direct oral anticoagulant and low molecular weight heparin. 7) Patients who do not have been diagnosed to be IBD, such as IBD unclassified. 8) Patients who do not agree with participation of this study regardless of explanation and consent forms.

发起方

Asahikawa Medical Universtity